BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

488 related articles for article (PubMed ID: 23952102)

  • 1. Impact of cyclosporine versus tacrolimus on the incidence of de novo malignancy following liver transplantation: a single center experience with 609 patients.
    Wimmer CD; Angele MK; Schwarz B; Pratschke S; Rentsch M; Khandoga A; Guba M; Jauch KW; Bruns C; Graeb C
    Transpl Int; 2013 Oct; 26(10):999-1006. PubMed ID: 23952102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.
    Tjon AS; Sint Nicolaas J; Kwekkeboom J; de Man RA; Kazemier G; Tilanus HW; Hansen BE; van der Laan LJ; Tha-In T; Metselaar HJ
    Liver Transpl; 2010 Jul; 16(7):837-46. PubMed ID: 20583092
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adult liver transplantation and steroid-azathioprine withdrawal in cyclosporine (Sandimmun)-based immunosuppression - 5 year results of a prospective study.
    Lerut JP; Ciccarelli O; Mauel E; Gheerardhyn R; Talpe S; Sempoux C; Laterre PF; Roggen FM; Van Leeuw V; Otte JB; Gianello P
    Transpl Int; 2001 Dec; 14(6):420-8. PubMed ID: 11793040
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tacrolimus and cyclosporine have differential effects on the risk of development of bronchiolitis obliterans syndrome: results of a prospective, randomized international trial in lung transplantation.
    Treede H; Glanville AR; Klepetko W; Aboyoun C; Vettorazzi E; Lama R; Bravo C; Knoop C; Aubert JD; Reichenspurner H;
    J Heart Lung Transplant; 2012 Aug; 31(8):797-804. PubMed ID: 22554673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. De novo cancer in cyclosporine-treated and non-cyclosporine-treated adult primary renal allograft recipients.
    Gruber SA; Gillingham K; Sothern RB; Stephanian E; Matas AJ; Dunn DL
    Clin Transplant; 1994 Aug; 8(4):388-95. PubMed ID: 7949545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term evaluation of cyclosporine and tacrolimus based immunosuppression in pediatric liver transplantation.
    Hasenbein W; Albani J; Englert C; Spehr A; Grabhorn E; Kemper MJ; Burdelski M; Ganschow R
    Pediatr Transplant; 2006 Dec; 10(8):938-42. PubMed ID: 17096762
    [TBL] [Abstract][Full Text] [Related]  

  • 7. De novo malignancies in renal transplant recipients: experience at a single center with 1882 transplant patients over 39 yr.
    Apel H; Walschburger-Zorn K; Häberle L; Wach S; Engehausen DG; Wullich B
    Clin Transplant; 2013; 27(1):E30-6. PubMed ID: 23278453
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The 28-year incidence of de novo malignancies after liver transplantation: A single-center analysis of risk factors and mortality in 1616 patients.
    Rademacher S; Seehofer D; Eurich D; Schoening W; Neuhaus R; Oellinger R; Denecke T; Pascher A; Schott E; Sinn M; Neuhaus P; Pratschke J
    Liver Transpl; 2017 Nov; 23(11):1404-1414. PubMed ID: 28590598
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term follow-up of de novo allergy in pediatric liver transplantation--10 yr experience of a single center.
    Lee Y; Lee YM; Kim MJ; Lee SK; Choe YH
    Pediatr Transplant; 2013 May; 17(3):251-5. PubMed ID: 23405954
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S; He X; Yang L; Ma Y; Zhu X; Ju W; Huang J
    Exp Clin Transplant; 2008 Jun; 6(2):113-7. PubMed ID: 18816237
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of solid organ cancers after liver transplantation: comparison with regional cancer incidence rates and risk factors.
    Carenco C; Faure S; Herrero A; Assenat E; Duny Y; Danan G; Bismuth M; Chanques G; Ursic-Bedoya J; Jaber S; Larrey D; Navarro F; Pageaux GP
    Liver Int; 2015 Jun; 35(6):1748-55. PubMed ID: 25488375
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evidence of differential risk for posttransplantation malignancy based on pretransplantation cause in patients undergoing liver transplantation.
    Saigal S; Norris S; Muiesan P; Rela M; Heaton N; O'Grady J
    Liver Transpl; 2002 May; 8(5):482-7. PubMed ID: 12004349
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Non-lymphoid cancer after liver transplantation.
    Frezza EE; Fung JJ; van Thiel DH
    Hepatogastroenterology; 1997; 44(16):1172-81. PubMed ID: 9261620
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative incidence of de novo nonlymphoid malignancies after liver transplantation under tacrolimus using surveillance epidemiologic end result data.
    Jain AB; Yee LD; Nalesnik MA; Youk A; Marsh G; Reyes J; Zak M; Rakela J; Irish W; Fung JJ
    Transplantation; 1998 Nov; 66(9):1193-200. PubMed ID: 9825817
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo malignancies after kidney and liver transplantations: experience on 582 consecutive cases.
    Baccarani U; Adani GL; Montanaro D; Risaliti A; Lorenzin D; Avellini C; Tulissi P; Groppuzzo M; Currò G; Luvisetto F; Beltrami A; Bresadola V; Viale PL; Bresadola F
    Transplant Proc; 2006 May; 38(4):1135-7. PubMed ID: 16757287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Serum cholesterol changes in long-term survivors of liver transplantation: a comparison between cyclosporine and tacrolimus therapy.
    Charco R; Cantarell C; Vargas V; Capdevila L; Lázaro JL; Hidalgo E; Murio E; Margarit C
    Liver Transpl Surg; 1999 May; 5(3):204-8. PubMed ID: 10226111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of tacrolimus compared with cyclosporin A microemulsion in renal transplantation: 2 year follow-up results.
    Krämer BK; Montagnino G; Del Castillo D; Margreiter R; Sperschneider H; Olbricht CJ; Krüger B; Ortuño J; Köhler H; Kunzendorf U; Stummvoll HK; Tabernero JM; Mühlbacher F; Rivero M; Arias M;
    Nephrol Dial Transplant; 2005 May; 20(5):968-73. PubMed ID: 15741208
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary immunosuppression with tacrolimus after liver transplantation: 12-years follow-up.
    Jonas S; Neuhaus R; Junge G; Klupp J; Theruvat T; Langrehr JM; Settmacher U; Neuhaus P
    Int Immunopharmacol; 2005 Jan; 5(1):125-8. PubMed ID: 15589470
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term outcomes in liver transplant patients with hepatic C infection receiving tacrolimus or cyclosporine.
    Villamil F; Levy G; Grazi GL; Mies S; Samuel D; Sanjuan F; Rossi M; Lake J; Munn S; Mühlbacher F; Leonardi L; Cillo U
    Transplant Proc; 2006 Nov; 38(9):2964-7. PubMed ID: 17112875
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Burden of de novo malignancy in the liver transplant recipient.
    Chandok N; Watt KD
    Liver Transpl; 2012 Nov; 18(11):1277-89. PubMed ID: 22887956
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.